Светлый фон

32. Taylor M. Participants in rogue herpes vaccine research take legal action. Kaiser Health News. March 13, 2018. Available at: https://khn.org/news/participants-in-rogue-herpes-vaccine-research-take-legal-action/. Accessed June 25, 2018.

33. Oseso L, Magaret A. S, Jerome K. R, Fox J, Wald A. Attitudes and willingness to assume risk of experimental therapy to eradicate genital herpes simplex virus infection. Sex Transm Dis. 2016 Sep;43(9):566–71.

Sex Transm Dis.

34. Phipps W, Saracino M, Magaret A, Selke S, Remington M, Huang M. L., Warren T, Casper C, Corey L, Wald A. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis. 2011 Jan 15;203(2):180–7.

J Infect Dis.

35. Tronstein E, Johnston C, Huang M. L., Selke S, Magaret A, Warren T, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305(14):1441–9.

JAMA.

36. Johnston C, Zhu J, Jing L, Laing K. J, McClurkan C M., Klock A, Diem K, Jin L, Stanaway J, Tronstein E, Kwok W. W., Huang M. L., Selke S, Fong Y, Magaret A, Koelle D. M., Wald A, Corey L. Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. J Virol. 2014 May;88(9):4921–31.

J Virol.

37. Xu F, Sternberg M. R., Kottiri B. J., McQuillan G. M., Lee F. K., Nahmias A. J., Berman S. M., Markowitz L. E. Trends in herpes simplex virus Type 1 and Type 2 seroprevalence in the United States. JAMA. 2006 Aug 23;296(8):964–73.

Type 1 Type 2 JAMA.

38. Satterwhite C. L., Torrone E, Meites E, Dunne E. F., Mahajan R., Ocfemia M. C., Su J, Xu F, Weinstock H. Sexually transmitted infections among U.S. women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013 Mar;40(3):187–93.

Sex Transm Dis.

39. McQuillan G., Kruszon-Moran D., Flagg E. W., Paulose-Ram R. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14–49: United States, 2015–2016. NCHS Data Brief, no. 304. Hyattsville, M. D: National Center for Health Statistics; 2018.

Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14–49: United States, 2015–2016.

40. Bernstein D. I., Bellamy A. R., Hook E. W. 3rd, Levin M. J., Wald A, Ewell M. G., Wolff P. A., Deal C. D., Heineman T. C., Dubin G, Belshe R. B. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus Type 1 and Type 2 in young women. Clin Infect Dis. 2013 Feb;56(3):344–51.

 D. I., Type 1